Detalhe da pesquisa
1.
CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells.
Immunity
; 53(4): 805-823.e15, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33053330
2.
Tumor necrosis factor superfamily 14 (LIGHT) controls thymic stromal lymphopoietin to drive pulmonary fibrosis.
J Allergy Clin Immunol
; 136(3): 757-68, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25680454
3.
NKG7 Is Required for Optimal Antitumor T-cell Immunity.
Cancer Immunol Res
; 10(2): 154-161, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35013002
4.
ACKR4 restrains antitumor immunity by regulating CCL21.
J Exp Med
; 217(6)2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32289156
5.
CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function.
Cancer Immunol Res
; 7(4): 559-571, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30894377
6.
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.
Cancer Discov
; 9(12): 1754-1773, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31699796
7.
CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.
J Clin Invest
; 128(6): 2613-2625, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29757192
8.
CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.
J Clin Invest
; 132(6)2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35289314
9.
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.
Cancer Discov
; 6(4): 446-59, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26787820